BioLineRx (BLRX) to Release Quarterly Earnings on Monday

BioLineRx (NASDAQ:BLRX) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $0.4920 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 23, 2026 at 8:30 AM ET.

BioLineRx Stock Performance

Shares of BLRX stock opened at $2.65 on Friday. The company has a market cap of $11.53 million, a P/E ratio of 15.59 and a beta of 1.31. The firm has a 50-day moving average of $2.86 and a 200-day moving average of $3.26. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.09 and a quick ratio of 1.93. BioLineRx has a one year low of $2.30 and a one year high of $7.77.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.